Literature DB >> 21044427

Increases in use of methotrexate since the 1980s.

T Sokka1.   

Abstract

In this chapter, we review the use of DMARDs in several clinical RA cohorts and databases between the 1970s and the 2000s. The DMARD profile in the QUEST-RA database provides an overview of clinical use of MTX in recent years in 25 countries. The data show that (I) MTX is currently the most frequently used DMARD in RA, and (II) that this development has taken about 20 years to emerge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044427

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.

Authors:  Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon
Journal:  Semin Arthritis Rheum       Date:  2014-08-27       Impact factor: 5.532

2.  Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.

Authors:  Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon
Journal:  J Rheumatol       Date:  2014-10-15       Impact factor: 4.666

3.  Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Authors:  Gabriela Schmajuk; Yinghui Miao; Jinoos Yazdany; W John Boscardin; David I Daikh; Michael A Steinman
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

4.  Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate.

Authors:  Gabriela Schmajuk; Chris Tonner; Yinghui Miao; Jinoos Yazdany; Jacqueline Gannon; W John Boscardin; David I Daikh; Michael A Steinman
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

5.  In vitro inhibition of HUVECs by low dose methotrexate - insights into oral adverse events.

Authors:  Tobias Annussek; Thomas Szuwart; Johannes Kleinheinz; Cathrin Koiky; Kai Wermker
Journal:  Head Face Med       Date:  2014-05-22       Impact factor: 2.151

6.  Acute methotrexate ingestions in adults: a report of serious clinical effects and treatments.

Authors:  Vikhyat S Bebarta; Matthew D Hensley; Douglas J Borys
Journal:  J Toxicol       Date:  2014-04-16

Review 7.  Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis.

Authors:  Alfonso E Bello; Elizabeth L Perkins; Randy Jay; Petros Efthimiou
Journal:  Open Access Rheumatol       Date:  2017-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.